The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Efficacy of low-dose spironolactone in subjects with resistant hypertension
Open accessAbstract
BACKGROUND: Previous reports have demonstrated the antihypertensive efficacy of high doses of spironolactone in subjects with primary aldosteronism and, to a lesser degree, subjects with resistant hypertension. METHODS: In current analysis, we examined the antihypertensive benefit of adding low-dose spironolactone to multidrug regimens that included a diuretic and an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) in subjects with resistant hypertension with and without primary aldosteronism. Subjects referred for resistant hypertension were evaluated with an early morning plasma renin activity, 24-h urinary aldosterone and sodium during a high dietary salt ingestion. The diagnosis of primary aldosteronism was confirmed with a renin activity <1.0 ng/mL/h, urinary aldosterone >12 mug/24 h and urinary sodium >200 mEq/24 h. After biochemical evaluation, spironolactone (12.5 to 25 mg/d) was added to each subject's antihypertensive regimen. If blood pressure (BP) remained uncontrolled, the dose of spironolactone was titrated up to 50 mg/d. Follow-up BP was determined at 6 weeks, 3 months, and 6 months. RESULTS: A total number of 76 subjects were included in the analysis, 34 of whom had biochemical primary aldosteronism. Low-dose spironolactone was associated with an additional mean decrease in BP of 21 +/- 21/10 +/- 14 mm Hg at 6 weeks and 25 +/- 20/12 +/- 12 mm Hg at 6-month follow-up. The BP reduction was similar in subjects with and without primary aldosteronism and was additive to the use of ACE inhibitors, ARBs, and diuretics. CONCLUSIONS: We conclude that low-dose spironolactone provides significant additive BP reduction in African American and white subjects with resistant hypertension with and without primary aldosteronism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension
Calhoun, D. A., Nishizaka, M. K., Zaman, M. A., Thakkar, R. B., & Weissmann, P. (2002) · Hypertension · doi:10.1161/01.hyp.0000040261.30455.b6 · Cited by 763
Self-citationMcKelvie, R. S., Yusuf, S., Pericak, D., Avezum, A., Burns, R. J., Probstfield, J., Tsuyuki, R. T., White, M., Rouleau, J., Latini, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.10.1056 · Cited by 692
Drug Effects on Aldosterone/Plasma Renin Activity Ratio in Primary Aldosteronism
Mulatero, P., Rabbia, F., Milan, A., Paglieri, C., Morello, F., Chiandussi, L., & Veglio, F. (2002) · Hypertension · doi:10.1161/01.hyp.0000038478.59760.41 · Cited by 392
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
Weinberger, M. H., Roniker, B., Krause, S. L., & Weiss, R. J. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)02957-6 · Cited by 388
Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
STAESSEN, J., LIJNEN, P., FAGARD, R., VERSCHUEREN, L. J., & AMERY, A. (1981) · Journal of Endocrinology · doi:10.1677/joe.0.0910457 · Cited by 339
Efficacy and tolerance of spironolactone in essential hypertension
Jeunemaitre, X., Chatellier, G., Kreft-Jais, C., Charru, A., Devries, C., Plouin, P.-F., Corvol, P., & Menard, J. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)91030-7 · Cited by 276
Schepkens, H., Vanholder, R., Billiouw, J.-M., & Lameire, N. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00642-8 · Cited by 262
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients
Flack, J. M., Oparil, S., Pratt, J. H., Roniker, B., Garthwaite, S., Kleiman, J. H., Yang, Y., Krause, S. L., Workman, D., & Saunders, E. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00054-8 · Cited by 224
Cited by
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Williams, B., MacDonald, T. M., Morant, S., Webb, D. J., Sever, P., McInnes, G., Ford, I., Cruickshank, J. K., Caulfield, M. J., Salsbury, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00257-3 · Cited by 1,308
Prevalence of Resistant Hypertension in the United States, 2003–2008
Persell, S. D. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.170308 · Cited by 761
Mechanisms of Sympathetic Activation in Obesity-Related Hypertension
Esler, M., Straznicky, N., Eikelis, N., Masuo, K., Lambert, G., & Lambert, E. (2006) · Hypertension · doi:10.1161/01.hyp.0000242642.42177.49 · Cited by 443
Weber, M. A., Black, H., Bakris, G., Krum, H., Linas, S., Weiss, R., Linseman, J. V., Wiens, B. L., Warren, M. S., & Lindholm, L. H. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61500-2 · Cited by 334
Metadata
- Authors
- Nishizaka, M.
- Venue
- American Journal of Hypertension
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-11
- Volume
- 16
- Issue
- 11
- Pages
- 925-930
- ISSN
- 0895-7061 (ISSN-L)
- OpenAlex
- W2064532153
- Cited by
- 502
- References
- 26
- FWCI
- 11.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of low-dose spironolactone in subjects with resistant hypertension. https://app.cochat.ai/papers/10.1016/s0895-7061(03)01032-x
- The paper
- Nishizaka, M. (2003). Efficacy of low-dose spironolactone in subjects with resistant hypertension. American Journal of Hypertension. https://doi.org/10.1016/s0895-7061(03)01032-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.